Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee

Br J Cancer. 1991 Dec;64(6):1187-8. doi: 10.1038/bjc.1991.488.


Fourteen patients with advanced breast cancer were treated with the ribonucleotide reductase inhibitor didox 6 g m-2 given by intravenous infusion over 36 h every 3 weeks. None responded and toxicity was minimal. Possibilities for the more effective use of this agent are discussed.

Publication types

  • Clinical Trial

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Drug Evaluation
  • Humans
  • Hydroxamic Acids / therapeutic use*
  • Ribonucleotide Reductases / antagonists & inhibitors


  • Antimetabolites, Antineoplastic
  • Hydroxamic Acids
  • Ribonucleotide Reductases
  • 3,4-dihydroxybenzohydroxamic acid